Potential mechanisms of benefit with thalidomide in chronic heart failure

American Journal of Cardiovascular Drugs

Volumn 7, Issue 2, 2007, Pages 127-134

  Aukrust, P̊al ^a,b   Yndestad, Arne ^a   Dam̊as, Jan Kristian ^a   Ueland, Thor ^a   Øie, Erik ^a   Gullestad, Lars ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETANERCEPT; IMMUNOGLOBULIN; MATRIX METALLOPROTEINASE; PENTOXIFYLLINE; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FATIGUE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VEIN THROMBOSIS; VERTIGO;

ANIMALS; CARDIAC OUTPUT, LOW; FIBROSIS; HEART RATE; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; NEUTROPHILS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249111899     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707020-00004     Document Type: Review

References (66)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003 May 15; 348 (20): 2007-18
2. Mann DL, Deswal A, Bozkurt B, et al. New therapeutics for chronic heart failure. Annu Rev Med 2002; 53: 59-74
3. Aukrust P, Gullestad L, Ueland T, et al. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005; 37 (2): 74-85
4. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990 Jul 26; 323 (4): 236-41
5. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999 Feb 1; 83 (3): 376-82
6. Aukrust P, Ueland T, Müller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998 Mar 31; 97 (12): 1136-43
7. Damås JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure: possible role of platelets and monocytes. Cardiovasc Res 2000 Jan 14; 45 (2): 428-36
8. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001 Apr 24; 103 (16): 2055-9
9. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996 Feb 15; 93 (4): 704-11
10. Eiken HG, Øie E, Damås JK, et al. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 2001 May; 31 (5): 389-97
11. Damås JK, Eiken HG, Øie E, et al. Myocardial expression of CC- and CXCchemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000 Sep; 47 (4): 778-87
12. Bozkurt B, Kribbs SB, Clubb Jr FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998 Apr 14; 97 (14): 1382-91
13. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001 Aug 14; 104 (7): 826-31
14. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002 Nov 29; 91 (11): 988-98
15. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004 Apr 6; 109 (13): 1594-602
16. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 2003 Jul 1; 107 (25): 3133-40
17. Anker SD, Coats AJS. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002 Dec; 86 (2-3): 123-30
18. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001 Nov; 121 (5): 1145-57
19. Fisher Jr CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: the Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996 Jun 27; 334 (26): 1697-702
20. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003; 65: 81-101
21. Aukrust P, Yndestad A, Ueland T, et al. Anti-inflammatory trials in chronic heart failure. Heart Fail Monit 2006; 5 (1): 2-9
22. Agoston I, Dibbs ZI, Wang F, et al. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Card Fail 2002 Oct; 8 (5): 306-14
23. Gullestad L, Semb AG, Holt E, et al. Effect of thalidomide in patients with chronic heart failure. Am Heart J 2002 Nov; 144 (5): 847-50
24. Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005 Nov 29; 112 (22): 3408-14
25. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004 May 29; 363 (9423): 1802-11
26. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999 Dec; 20 (12): 538-40
27. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005 Aug; 153 (2): 254-73
28. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol 2004 Aug; 15 (8): 1151-60
29. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002; 53: 629-57
30. Davey PP, Ashrafian H. New therapies for heart failure: is thalidomide the answer? Q J Med 2000 May; 93 (5): 305-11
31. Gordinier ME, Dizon DS. Dyspnea during thalidomide treatment for advanced ovarian cancer. Annals Pharmacother 2005 May; 39 (5): 962-5
32. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic Proc 2005 Dec; 80 (12): 1549-51
33. Yndestad A, Vinge LE, Bjornerheim R, et al. Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. Eur J Heart Fail 2006 Dec; 8 (8): 790-6
34. Vescovo G, Ravara B, Angelini A, et al. Effect of thalidomide on the skeletal muscle in experimental heart failure. Eur J Heart Fail 2002 Aug; 4 (4): 455-60
35. Orea-Tejeda A, Arrieta-Rodriguez O, Castillo-Martinez L, et al. Effects of thalidomide treatment in heart failure patients. Cardiology 2006 Nov 9; 108 (4): 237-42
36. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999 Nov; 58 Suppl. 1: I107-13
37. Teo SK, Resztak KE, Scheffler MA, et al. Thalidomide in the treatment of leprosy. Microbes Infect 2002 Sep; 4 (11): 1193-202
38. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001 Dec; 115 (3): 605-8
39. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000 Nov; 97 (2): 109-20
40. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998 Nov 14; 352 (9140): 1586-9
41. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002 Mar 15; 168 (6): 2644-51
42. Yndestad A, Holm AM, Müller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003 Oct 15; 60 (1): 141-6
43. Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant 2000 Sep; 19 (9): 819-24
44. Haslett PA, Roche P, Butlin CR, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 2005 Dec 15; 192 (12): 2045-53
45. Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999 Sep 1; 15 (13): 1169-79
46. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999 Jul 1; 163 (1): 380-6
47. Lee ES, Kim YA, Kwon HJ, et al. Thalidomide upregulates macrophage inflammatory protein-1alpha in a herpes simplex virus-induced Behçet's disease-like animal model. Arch Dermatol Res 2004 Sep; 296 (4): 175-81
48. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004 Aug; 4 (4): 408-14
49. Yasui K, Kobayashi N, Yamazaki T, et al. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des 2005; 11 (3): 395-401
50. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004 Feb 15; 61 (3): 481-97
51. Mitsuke Y, Lee JD, Shimizu H, et al. Nitric oxide synthase activity in peripheral polymorphonuclear leukocytes in patients with chronic congestive heart failure. Am J Cardiol 2001 Jan 15; 87 (2): 183-7
52. Juffermans NP, Verbon A, Schultz MJ, et al. Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob Agents Chemother 2001 May; 45 (5): 1547-9
53. Dunzendorfer S, Schratzberger P, Reinisch N, et al. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Naunyn Schmiedebergs Arch Pharmacol 1997 Nov; 356 (5): 529-35
54. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996 Mar; 31 (2-3): 213-21
55. Gelati M, Corsini E, Frigerio S, et al. Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J Neurooncol 2003 Sep; 64 (3): 193-201
56. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000 May; 46 (2): 214-24
57. Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 2000 May; 46 (2): 225-38
58. Yeh TS, Ho YP, Huang SF, et al. Thalidomide salvages lethal hepatic necroinflamamation and accelerates recovery from cirrhosis in rats. J Hepatol 2004 Oct; 41 (4): 606-12
59. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002 Mar 22; 90 (5): 520-30
60. Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 2004 Apr 15; 93 (8): 1052-5
61. Hamlin RL, Kijtawornrat A, Keene BW, et al. Effects of thalidomide on QTc, inotropy, and lusitropy in the isolated guinea pig heart. Cardiovasc Toxicol 2004; 4 (1): 29-36
62. Sharma RA, Steward WP, Daines CA, et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006 Sep; 42 (14): 2318-25
63. Anderson KC. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Semin Hematol 2005 Oct; 42 (4 Suppl. 4): S3-8
64. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004 Apr; 4 (4): 314-22
65. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999 May 25; 99 (20): 2645-51
66. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983 Oct; 2 (4): 755-63